Mark Lupo is an Endocrinology/Metabolic physician affiliated with University of South Florida Sarasota–Manatee. OpenAlex indexes 53 publications with 1,261 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3050 Bee Ridge Rd
Sarasota, FL 342397101
Telephone
941-342-9750Registry record last updated 28 Nov 2012.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascendis Pharma Endocrinology IncProgram year202523 payments$21,210openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202510 payments$13,145openpaymentsdata.cms.gov ↗
- ARGENX US, INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
98.8%l-Thyroxine85.2%Synthroid49%Levothyroxine Sodium43%Levoxyl4%Tirosint3%Unithroid1%Part D<11 patientsl-Triiodothyronine9.2%Liothyronine Sodium78%Cytomel22%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.2%Vitamin D3 Analog1.2%Calcitriol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease
The Journal of Clinical Endocrinology & Metabolism
2024 - Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid Cancer
Journal of the Endocrine Society
2023 - FRI537 Thyrotropin Receptor Blocking Antibodies - A Multicenter, 4-Assay Comparison
Journal of the Endocrine Society
2023
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”